| __timestamp | Arrowhead Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 9335772 |
| Thursday, January 1, 2015 | 34718089 | 12390000 |
| Friday, January 1, 2016 | 40998209 | 25602000 |
| Sunday, January 1, 2017 | 32022880 | 21262000 |
| Monday, January 1, 2018 | 19110051 | 28430000 |
| Tuesday, January 1, 2019 | 26556257 | 40849000 |
| Wednesday, January 1, 2020 | 52275890 | 60210000 |
| Friday, January 1, 2021 | 80981000 | 83664000 |
| Saturday, January 1, 2022 | 124431000 | 104097000 |
| Sunday, January 1, 2023 | 90932000 | 106916000 |
| Monday, January 1, 2024 | 98761000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Arrowhead Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have been at the forefront of this challenge since 2014. Over the years, Arrowhead has shown a steady increase in SG&A expenses, peaking in 2022 with a 410% rise from 2014. Meanwhile, Iovance's SG&A costs surged by over 1,000% during the same period, reflecting its aggressive growth strategy.
Interestingly, 2023 marked a shift, with Arrowhead reducing its SG&A expenses by 27% from the previous year, while Iovance continued its upward trend. This divergence highlights Arrowhead's strategic cost optimization efforts. However, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies navigate the biotech landscape, their SG&A strategies will be pivotal in determining their competitive edge.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE